Liquidia (LQDA) Cash from Investing Activities (2020 - 2026)
Liquidia (LQDA) posted quarterly Cash from Investing Activities of -$2.8 million for Q1 2026, down 757.58% year-over-year from $430368.7 in Q1 2025, and up 29.92% quarter-over-quarter from -$4.0 million in Q4 2025.
Liquidia (LQDA) Cash from Investing Activities (2020 - 2026) Analysis & Trends
Liquidia's Cash from Investing Activities history runs 7 years deep, the most recent figure standing at -$2.8 million for Q1 2026.
- In Q1 2026, Cash from Investing Activities fell 757.58% year-over-year to -$2.8 million; the TTM figure through Mar 2026 stood at -$8.8 million (down 8.46% YoY), while the FY2025 annual figure was -$6.3 million, up 24.94% from the prior year.
- Cash from Investing Activities for Q1 2026 stood at -$2.8 million, up from -$4.0 million in the prior quarter.
- The five-year high for Cash from Investing Activities was -$2000.0 in Q2 2022, with the low at -$10.5 million in Q3 2023.
- The 5-year median for Cash from Investing Activities is -$767500.0 (2024), against an average of -$1.8 million.
- The sharpest annual moves came in 2022 and 2023: Cash from Investing Activities surged 94.29% in 2022, then slumped 12050.0% in 2023.
- Liquidia's Cash from Investing Activities stood at -$491000.0 in 2022, then jumped by 58.04% to -$206000.0 in 2023, then slumped by 2220.39% to -$4.8 million in 2024, then grew by 15.52% to -$4.0 million in 2025, then advanced by 29.92% to -$2.8 million in 2026.
- Business Quant data shows LQDA's Cash from Investing Activities at -$2.8 million in Q1 2026, -$4.0 million in Q4 2025, and -$911000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.96 Bn | 43.00 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.23 Bn | 39.58 Bn | 2.15 Bn | -491.00 Mn |
| 3 | Zoetis | 31.76 Bn | 30.08 Bn | 1.05 Bn | -300.00 Mn |
| 4 | Takeda Pharmaceutical | 28.68 Bn | 22.88 Bn | 5.10 Bn | -550.24 Mn |
| 5 | United Therapeutics | 22.27 Bn | 19.61 Bn | 683.80 Mn | 87.50 Mn |
| 6 | Viatris | 18.69 Bn | 17.81 Bn | 1.46 Bn | -51.60 Mn |
| 7 | Neurocrine Biosciences | 15.56 Bn | 15.17 Bn | 935.80 Mn | -135.40 Mn |
| 8 | Elanco Animal Health | 11.78 Bn | 11.25 Bn | 798.00 Mn | -110.00 Mn |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.97 Bn | - | - |
| 10 | Liquidia | 6.38 Bn | 6.10 Bn | 160.92 Mn | -12.24 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -12.24 Mn |
| Jun 30, 2026 | -12.24 Mn |
| Mar 31, 2026 | -2.83 Mn |
| Mar 31, 2026 | -2.83 Mn |
| Dec 31, 2025 | -4.04 Mn |
| Dec 31, 2025 | -4.04 Mn |
| Sep 30, 2025 | -911,000.00 |
| Sep 30, 2025 | -911,000.00 |
| Jun 30, 2025 | -1.06 Mn |
| Jun 30, 2025 | -1.06 Mn |
| Mar 31, 2025 | -330,000.00 |
| Mar 31, 2025 | -330,000.00 |
| Dec 31, 2024 | -4.78 Mn |
| Dec 31, 2024 | -4.78 Mn |
| Sep 30, 2024 | -1.75 Mn |
| Sep 30, 2024 | -1.75 Mn |
| Jun 30, 2024 | -1.29 Mn |
| Jun 30, 2024 | -1.29 Mn |
| Mar 31, 2024 | -624,000.00 |
| Mar 31, 2024 | -624,000.00 |